WC
FDMT icon

Wexford Capital’s 4D Molecular Therapeutics FDMT Stock Holding History

Wexford Capital’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,676
Closed -$40.6K – 428
2025
Q3 		$40.6K Buy
+4,676
New +$27.9K 0.01% 325

Other funds holding FDMT

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Wexford Capital's FDMT Position: Q4 2025 in Review

Wexford Capital sold out of 4D Molecular Therapeutics (FDMT) in Q4 2025, closing a stake of 4,676 shares — an estimated $40.6K sold.

Wexford Capital first reported a position in FDMT in Q3 2025 and held it in 1 quarter. The position peaked at $40.6K in Q3 2025. 153 funds tracked by Wall St. Rank hold FDMT as of Q4 2025.

  • Wexford Capital reported no remaining 4D Molecular Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Wexford Capital sold 4,676 4D Molecular Therapeutics shares in Q4 2025, an estimated $40.6K.
  • Wexford Capital first reported a position in 4D Molecular Therapeutics in Q3 2025 and held it in 1 quarter.
  • Wexford Capital's 4D Molecular Therapeutics position peaked at $40.6K in Q3 2025.
  • 153 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q4 2025.

Based on Wexford Capital's 13F filing for Q4 2025, filed 13 Feb 2026.